

**Amendment to the Claims:**

This listing of claims will replace all prior versions and listing of claims in the application. Cancel Claim 8 without prejudice to the subject matter of this claim being pursued in this application at a later time or in a continuing application.

1. (Original) A method of treatment for atherosclerosis comprising administering a therapeutically effective amount of a compound selected from 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid and the pharmaceutically acceptable salts and esters thereof to a patient in need of such treatment.
2. (Original) The method of Claim 1 wherein the treatment comprises halting or slowing the progression of atherosclerosis.
3. (Original) The method of claim 2 wherein the treatment comprises halting or slowing atherosclerotic plaque progression.
4. (Original) The method of claim 3 wherein the treatment comprises halting or slowing progression of existing atherosclerotic plaques.
5. (Original) The method of claim 3 wherein the treatment comprises halting or slowing formation of new atherosclerotic plaques.
6. (Original) The method of claim 1 wherein the treatment comprises regression of atherosclerosis.
7. (Original) The method of claim 6 wherein the treatment comprises regression of atherosclerotic plaque.
8. (Cancelled).

9. (Original) The method of Claim 1 further comprising administration of a therapeutically effective amount of an additional anti-atherosclerotic agent in combination with the compound of Claim 1.

10. (Original) The method of Claim 9 wherein the additional anti-atherosclerotic agent is an HMG-CoA reductase inhibitor.

11. (Original) A method for preventing or reducing the risk of atherosclerotic plaque rupture comprising administering a prophylactically effective amount of a compound selected from 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid and the pharmaceutically acceptable salts and esters thereof to a patient in need of such treatment.

12. (Original) The method of Claim 11 wherein the compound is the sodium salt of 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid.

13. (Original) The method of Claim 11 further comprising administration of a therapeutically effective amount of an additional anti-atherosclerotic agent in combination with the compound of Claim 11.

14. (Original) The method of Claim 13 wherein the additional anti-atherosclerotic agent is an HMG-CoA reductase inhibitor

15. (Original) A method for preventing or reducing the risk of developing atherosclerosis, comprising administering a prophylactically effective amount of a compound selected from 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid and the pharmaceutically acceptable salts and esters thereof to a patient in need of such treatment.

16. (Original) The method of Claim 15 wherein the compound is the sodium salt of 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid.

17. (Original) A method of treatment for atherosclerosis comprising administering a therapeutically effective amount of a FLAP inhibitor in combination with a therapeutically effective amount of an additional anti-atherosclerotic agent to a patient in need of such treatment.

18. (Original) The method of claim 17 wherein the additional anti-atherosclerotic agent is an HMG-CoA reductase inhibitor.

19. (Original) A method for preventing or reducing the risk of atherosclerotic plaque rupture comprising administering a prophylactically effective amount of a FLAP inhibitor in combination with a prophylactically effective amount of an additional anti-atherosclerotic agent to a patient in need of such treatment.

20. (Original) The method of claim 19 wherein the additional anti-atherosclerotic agent is an HMG-CoA reductase inhibitor.

21. (Original) A pharmaceutical composition comprising a FLAP inhibitor, a therapeutically effective amount of an HMG-CoA reductase inhibitor and pharmaceutically acceptable carrier.